Evaluation and predictive factors analyses for patient-self-reported depression, anxiety and quality of life in patients with metastatic renal cell carcinoma underwent interferon-α treatment: a prospective cohort study

Abstract

Background: This study aimed to investigate the patient-self-reported depression, anxiety and quality of life (QoL) as well as their predictive factors in patients with metastatic renal cell carcinoma (mRCC) underwent interferon-alpha (IFN-α) treatment.Methods: A total of 127 patients with mRCC underwent IFN-α treatment were consecutively enrolled in this prospective cohort study. Anxiety, depression and QoL were assessed at week 0 (W0), W4, W8 and W12 by Hospital Anxiety and Depression Scale (HADS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 Scale), respectively.Results: The percentages of anxiety and depression both increased at W12 compared with W0. The EORTC QLQ-C30 Scale-Global health status score, EORTC QLQ-C30 Scale-Function and EORTC QLQ-C30 Scale-Symptoms scores did not deteriorate at W4, W8 or W12 compared with W0. Multivariate logistic regression analyses revealed that older age and elevated level of highest education independently predict reduced risk of HADS-Anxiety score elevation at W12, while hypertension was an independent predictive factor for increased risk. Older age also independently associated with less risk of elevated HADS-Depression score. Smoke, hypertension, diabetes and higher ECOG performance were independent predicting factors for escalated risk of EORTC QLQ-C30 Scale-Global health status score elevation at W12, and higher ECOG performance was an independent predicting factor for increased risk of elevated EORTC QLQ-C30 Scale-Function score at W12. Conclusions:In conclusion, anxiety and depression increased while QoL did not deteriorate in mRCC patients during IFN-α treatment, and age, highest education, hypertension, smoke, diabetes as well as higher ECOG performance status correlated with their aggravation.

Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review

“…Three studies investigated the impact of psychological distress, anxiety and/or depression, on patients with metastatic RCC. Two studies included 304 patients from the US [ 29 , 30 ] and one included 127 patients from China [ 31 ]. Different instruments were used to measure distress, anxiety and/or depression including a touch screen-based instrument— either HADS or CES-D. A meta-analysis was not performed due to heterogeneity between studies.…”

“…), but statistical significance was not reached. In a prospective evaluation of a Chinese cohort, Wang et al [ 31 ] reported that, in patients with metastatic RCC, anxiety and depression increased 3 months after interferon-α treatment ( Table 3 ).…”

The protective effect of Lonicera japonica polysaccharide on mice with depression by inhibiting NLRP3 inflammasome

“…Depression is a serious life-threatening disorder that affects hundreds of millions of patients and may occur suddenly at all ages (1). This severe psychiatric disorder is the 4th leading cause of disability worldwide, which should be looked at more seriously, and it has a prevalence of above 15% (2). Depression is not a single disorder, but a heterogeneous syndrome which comprises of several symptoms of distinct causes and pathophysiology (3).…”

Active Surveillance in Metastatic Renal Cell Carcinoma

“…No significant changes were observed in patients on surveillance, suggesting that AS is well tolerated over time despite the probable progression in some of such patients. To compare, in one series of patients with mRCC receiving ST, 31% had depression prior to starting ST, which increased to 43% after 12 weeks of therapy (43). risk patients, these patients are probably be good AS candidates.…”